JAK2 and essential thrombocythemia: Molecular and genetic studies have shown that the JAK2 V617F is one of the molecular markers of MPDs as it has been detected in 31.3%-72.1% of patients with ET, 46.7%-100% of patients with PV, and 25.0%-85.7% of those with PMF [3-5].